COVID-19 International Drug Pregnancy Registry
Recruiting now
Conditions studied: Covid19
In brief
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Key facts
- Study ID
- NCT05013632
- Run by
- Pregistry
- People needed
- 2000
- Starts
- 2021-12-01
- Expected to finish
- 2027-09-30
- Last updated by the study team
- 2025-09-26
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment
- Age ≥18 years at time of enrollment
- With mild to severe COVID-19 during pregnancy
- Either
- Treated for COVID-19 with at least one of the medications included in Table 1 during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP or
- Hospitalized and did not receive any pharmacological treatment specifically indicated for mild, moderate, or severe COVID-19 during pregnancy
- Resident of a country where a Central Institutional Review Board (IRB) or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study
- Signed the informed consent form and submitted the baseline module "COVID-19 Medications During This Pregnancy"
You may not qualify if…
- ● <18 years of age
Where it is running
- Pregistry — Los Angeles, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.